Celcuity Inc.

NASDAQ:CELC

Biotechnology

Healthcare
$55.60 -4.59%

-$4.04 today

Market cap
$2.72B
Beta
0.12
P/E (TTM)
-23.7
EPS (TTM)
-$3.54
52W Low $11.28High $151.02

Volume 0.98M

Average 1.24M

CELC Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Celcuity Inc.NASDAQ: CELC

Research & Development · Q2 FY2026 · quarter ended Jun 2026

Research & development dips below year-ago levels

Q2 FY2026 research & development of $31.08M fell 22.7% year over year, behind the +2.4% change in trailing-twelve-month research & development. Sequentially, it fell 6.0% from the prior quarter. Over 3 fiscal years it compounded at +60.2% a year.

Context

  • Research & development increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -22.7% toward the trailing-twelve-month pace of +2.4%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$31.08M-6.0% QoQ
Last fiscal yearDec 2025
$145M+39.1% YoY
LTMJun 2026
$136.69M+2.4% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-22.7%——
1 year+39.1%——
3-year CAGR+60.2%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
145M USD
Year-over-year change
+39.1%
4-year CAGR
+54.0%

Research & Development vs competitors

How CELC compares with its peers on the latest reported figures

  • CELC's LTM Jun 2026 research & development of $136.69M is the highest of the 6 companies compared; the peer median is $53.69M.
  • Its year-over-year change of +2.4% is the 5th highest of 6, against a peer median of +6.9%.
  • Over three fiscal years its annual growth of +60.2% compares with a peer median of -1.6%.
CELC Competitors Peer median
Research & Development for CELC and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CELCCelcuity Inc.LTM Jun 2026$136.69M +2.4%+60.2%—
ADPTAdaptive Biotechnologies CorporationLTM Jun 2026$88.21M -7.8%-12.9%28.6%
BLLNBillionToOne, Inc.LTM Jun 2026$59.21M +38.6%—14.9%
CSTLCastle Biosciences, Inc.LTM Mar 2026$53.69M +5.8%+4.9%15.8%
PSNLPersonalis, Inc.LTM Mar 2026$52.16M +6.9%-8.2%80.9%
NEONeoGenomics, Inc.LTM Jun 2026$38.17M +9.5%+6.9%5.0%
Peer median (excluding CELC) $53.69M+6.9%-1.6%15.8%

Competitors are the stored peer set for CELC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue0000167K
Gross Profit0000(167K)
Gross Margin—————
Research & Development25.76M35.29M60.59M104.2M145M
Selling, General & Admin2.6M4.38M5.64M9.06M27.2M
Operating Expenses28.36M39.39M66.23M113.27M172.19M
Depreciation & Amortization303.24K210.92K142.77K129.95K167K
EBITDA(28.04M)(38.05M)(58.31M)(101.37M)(159.73M)
EBITDA Margin—————
Operating Income(28.36M)(39.39M)(66.23M)(113.27M)(172.19M)
Operating Margin—————
Interest Income13.26K1.13M7.78M11.77M12.3M
Interest Expense1.26M2.11M5.33M10.28M17.15M
Other Income / Expenses(1.25M)(978.95K)2.45M1.49M(4.85M)
Income Before Tax(29.61M)(40.37M)(63.78M)(111.78M)(177.04M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income(29.61M)(40.37M)(63.78M)(111.78M)(177.04M)
Net Margin—————
EPS (Basic)(2.28)(2.68)(2.69)(2.83)(3.78)
EPS (Diluted)(2.28)(2.68)(2.69)(2.83)(3.78)
Weighted Avg Shares13.38M15.42M23.68M39.45M52.54M
Weighted Avg Shares (Diluted)13.38M15.42M23.68M39.45M52.54M

Celcuity Inc.

NASDAQ:CELC

Intrinsic Alpha fair value

Locked

Current Price

$55.60

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.